A non-inferiority study of apatinib versus bevacizumab combined with XELOX regimen in the treatment of metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
Interventions: Experimental group:Apatinib 250mg po, qd, continuous taken; XELOX: Oxaliplatin 135 mg/m2 Ivgtt d1, Capecitabine 1000mg/m2 d1-14, q3w;Control group:Bevacizumab 7.5mg/kg, q3w; XELOX: Oxaliplatin 135 mg/m2 Ivgtt d1, Capecitabine 1000mg/m2 d1-14, q3w Primary outcome(s): Progress-free survival (PFS) Study Design: Non randomized control
创建时间：
2019-10-15
